The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Roman Perez-Soler

Division of Medical Oncology

Department of Oncology

Montefiore Medical Center

Albert Einstein College of Medicine



Name/email consistency: high



  • Division of Medical Oncology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, USA. 2002 - 2009
  • Albert Einstein College of Medicine, Bronx, NY 10467, USA. 2006


  1. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Pérez-Soler, R. Oncogene (2009) [Pubmed]
  2. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Perez-Soler, R. Clin. Cancer Res. (2007) [Pubmed]
  3. Clinical research of EGFR inhibitors and related dermatologic toxicities. Perez-Soler, R., Van Cutsem, E. Oncology (Williston Park, N.Y.) (2007) [Pubmed]
  4. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Perez-Soler, R. Clin. Lung. Cancer (2006) [Pubmed]
  5. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Pérez-Soler, R., Delord, J.P., Halpern, A., Kelly, K., Krueger, J., Sureda, B.M., von Pawel, J., Temel, J., Siena, S., Soulières, D., Saltz, L., Leyden, J. Oncologist (2005) [Pubmed]
  6. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. Peréz-Soler, R., Saltz, L. J. Clin. Oncol. (2005) [Pubmed]
  7. HER1/EGFR targeting: refining the strategy. Pérez-Soler, R. Oncologist (2004) [Pubmed]
  8. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. Pérez-Soler, R., Chachoua, A., Hammond, L.A., Rowinsky, E.K., Huberman, M., Karp, D., Rigas, J., Clark, G.M., Santabárbara, P., Bonomi, P. J. Clin. Oncol. (2004) [Pubmed]
  9. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Perez-Soler, R. Clin. Lung. Cancer (2004) [Pubmed]
  10. Tyrosine kinase inhibitors: a clinical perspective. Goel, S., Mani, S., Perez-Soler, R. Curr. Oncol. Rep (2002) [Pubmed]
WikiGenes - Universities